From my understanding, AC5 is only being tested to determine if it seals and prevents leaks. This sounds like a rapid and inexpensive study to me.
Some investors don't realize that the time it takes for a product to reach the market depends on the clinical process. This is a great reason to be bullish AC5; it is an innovating product in a segment that has not innovated in 100 years.
I like what this company is endeavoring into--and you all make good points here. 1000s of surgical procedures are performed on a daily basis that could benefit from a wound control product such as AC5. Nice long term investment here I feel.